JP2011523359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523359A5 JP2011523359A5 JP2011509642A JP2011509642A JP2011523359A5 JP 2011523359 A5 JP2011523359 A5 JP 2011523359A5 JP 2011509642 A JP2011509642 A JP 2011509642A JP 2011509642 A JP2011509642 A JP 2011509642A JP 2011523359 A5 JP2011523359 A5 JP 2011523359A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- chain sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 38
- 108090001123 antibodies Proteins 0.000 claims 38
- 239000000427 antigen Substances 0.000 claims 20
- 102000038129 antigens Human genes 0.000 claims 20
- 108091007172 antigens Proteins 0.000 claims 20
- 210000004027 cells Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 101710002779 LILRB3 Proteins 0.000 claims 3
- 101710030629 Lilrb3l Proteins 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000008929 regeneration Effects 0.000 claims 3
- 238000011069 regeneration method Methods 0.000 claims 3
- 210000003169 Central Nervous System Anatomy 0.000 claims 2
- 230000003376 axonal Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001537 neural Effects 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 1
- 208000006373 Bell Palsy Diseases 0.000 claims 1
- 208000001183 Brain Injury Diseases 0.000 claims 1
- 229960000860 Dapsone Drugs 0.000 claims 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Di(p-aminophenyl)sulphone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 102000018748 Immunoconjugates Human genes 0.000 claims 1
- 108010027440 Immunoconjugates Proteins 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000003627 Muscular Dystrophy Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims 1
- 206010011302 Peripheral nerve injury Diseases 0.000 claims 1
- 206010034606 Peripheral neuropathy Diseases 0.000 claims 1
- 206010036181 Porphyria Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 101700014436 RTN4 Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 1
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 1
- 206010050040 VIIth nerve paralysis Diseases 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000014511 neuron projection development Effects 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000000750 progressive Effects 0.000 claims 1
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 230000002588 toxic Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 200000000019 wound Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5294908P | 2008-05-13 | 2008-05-13 | |
| US61/052,949 | 2008-05-13 | ||
| US12/208,883 | 2008-09-11 | ||
| US12/208,883 US20100047232A1 (en) | 2006-11-14 | 2008-09-11 | Modulators of neuronal regeneration |
| US12/316,130 | 2008-12-09 | ||
| US12/316,130 US20090232794A1 (en) | 2007-12-11 | 2008-12-09 | Modulators of neuronal regeneration |
| PCT/US2009/043757 WO2009140361A1 (fr) | 2008-05-13 | 2009-05-13 | Anticorps anti-pirb |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011523359A JP2011523359A (ja) | 2011-08-11 |
| JP2011523359A5 true JP2011523359A5 (fr) | 2012-07-05 |
Family
ID=41319035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509642A Pending JP2011523359A (ja) | 2008-05-13 | 2009-05-13 | 抗ＰｉｒＢ抗体 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2291405A1 (fr) |
| JP (1) | JP2011523359A (fr) |
| KR (1) | KR20110011676A (fr) |
| CN (1) | CN102089327A (fr) |
| AR (1) | AR071777A1 (fr) |
| AU (1) | AU2009246443A1 (fr) |
| BR (1) | BRPI0912769A2 (fr) |
| CA (1) | CA2723430A1 (fr) |
| IL (1) | IL209129A0 (fr) |
| MX (1) | MX2010012299A (fr) |
| PE (1) | PE20091969A1 (fr) |
| RU (1) | RU2010150754A (fr) |
| TW (1) | TW200950808A (fr) |
| WO (1) | WO2009140361A1 (fr) |
| ZA (1) | ZA201007976B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011091177A1 (fr) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anticorps anti-ilt5 et fragments d'anticorps se liant à ilt5 |
| WO2011091181A1 (fr) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunorégulation par des anticorps anti-ilt5 et fragments d'anticorps se liant à ilt5 |
| ES2655077T3 (es) * | 2012-04-17 | 2018-02-16 | Mayo Foundation For Medical Education And Research | Anticuerpos humanos y secuencias de unión específicos del mismo para uso en accidente cerebrovascular e isquemia y condiciones isquémicas |
| CN103130898B (zh) * | 2013-01-28 | 2014-03-26 | 中国人民解放军第四军医大学 | Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用 |
| KR20200103706A (ko) | 2017-12-22 | 2020-09-02 | 조운스 테라퓨틱스, 인크. | Lilrb2에 대한 항체 |
| TW202428604A (zh) | 2018-07-09 | 2024-07-16 | 美商戊瑞治療有限公司 | 結合至ilt4的抗體 |
| CN109439661B (zh) * | 2018-10-22 | 2020-10-23 | 西安医学院 | 抑制pirB表达的短发卡shRNA、慢病毒及其应用 |
| AU2021265801A1 (en) | 2020-05-01 | 2022-11-17 | Ngm Biopharmaceuticals, Inc. | ILt-binding agents and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003041650A2 (fr) * | 2001-11-14 | 2003-05-22 | Immunex Corporation | Modulation de la fonction des lir dans le traitement de la polyarthrite rhumatoide |
| JP2009529490A (ja) * | 2006-01-23 | 2009-08-20 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ニューロンの可塑性および再生を増強するための組成物および方法 |
-
2009
- 2009-05-13 AU AU2009246443A patent/AU2009246443A1/en not_active Abandoned
- 2009-05-13 CA CA2723430A patent/CA2723430A1/fr not_active Abandoned
- 2009-05-13 JP JP2011509642A patent/JP2011523359A/ja active Pending
- 2009-05-13 EP EP09747445A patent/EP2291405A1/fr not_active Withdrawn
- 2009-05-13 PE PE2009000673A patent/PE20091969A1/es not_active Application Discontinuation
- 2009-05-13 WO PCT/US2009/043757 patent/WO2009140361A1/fr active Application Filing
- 2009-05-13 AR ARP090101723A patent/AR071777A1/es not_active Application Discontinuation
- 2009-05-13 CN CN2009801265242A patent/CN102089327A/zh active Pending
- 2009-05-13 RU RU2010150754/10A patent/RU2010150754A/ru not_active Application Discontinuation
- 2009-05-13 TW TW098115945A patent/TW200950808A/zh unknown
- 2009-05-13 BR BRPI0912769A patent/BRPI0912769A2/pt not_active IP Right Cessation
- 2009-05-13 MX MX2010012299A patent/MX2010012299A/es active IP Right Grant
- 2009-05-13 KR KR1020107027786A patent/KR20110011676A/ko not_active Application Discontinuation
-
2010
- 2010-11-04 IL IL209129A patent/IL209129A0/en unknown
- 2010-11-08 ZA ZA2010/07976A patent/ZA201007976B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523359A5 (fr) | ||
| CN110799531B (zh) | 抗PHF-tau抗体及其用途 | |
| RU2010150754A (ru) | АНТИТЕЛА ПРОТИВ PirB | |
| HRP20192134T1 (hr) | Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2007514419A5 (fr) | ||
| WO2007068412A3 (fr) | Anticorps monoclonal | |
| WO2008114733A1 (fr) | Anticorps anti-claudine-4 | |
| JP2009545325A5 (fr) | ||
| HRP20150429T1 (hr) | Ip-10 antitijela i njihove uporabe | |
| JP2020513791A5 (fr) | ||
| JP2009519718A5 (fr) | ||
| JP2019527194A5 (fr) | ||
| JP2010526028A5 (fr) | ||
| WO2009052081A4 (fr) | Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations | |
| JP2019530431A5 (fr) | ||
| JP2014502150A5 (fr) | ||
| MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
| JP2009518039A5 (fr) | ||
| JP2009525764A5 (fr) | ||
| JP2010532764A5 (fr) | ||
| JP2015529236A5 (fr) | ||
| JP2011527902A5 (fr) | ||
| WO2008060364A3 (fr) | Anticorps | |
| JP2009535021A5 (fr) |